Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Felmlee

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Clinical Liver Disease|April 18, 2019
Lipid interactions influence hepatitis C virus susceptibility and resistance to infectionIsaac Thom Shawa, David A Sheridan, Daniel J Felmlee, et al.
Plos One|April 23, 2014
Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein EMathieu Lefèvre, Daniel J Felmlee, Marie Parnot, et al.
Viruses|May 24, 2013
Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver diseaseDaniel J Felmlee, Mohamed Lamine Hafirassou, Mathieu Lefevre, et al.
The Lancet. Infectious Diseases|June 16, 2016
New perspectives for preventing hepatitis C virus liver graft infectionDaniel J Felmlee, Audrey Coilly, Raymond T Chung, et al.
Current Opinion in Virology|January 15, 2014
Entry of hepatitis B and C viruses - recent progress and future impactThomas F Baumert, Luke Meredith, Yi Ni, et al.
Journal of Hepatology|July 2, 2011
HCV and the hepatic lipid pathway as a potential treatment targetMargaret F Bassendine, David A Sheridan, Daniel J Felmlee, et al.
Microbial Pathogenesis|March 19, 2013
Hepatitis C virus vaccines--progress and perspectivesCatherine Fauvelle, Quentin Lepiller, Daniel J Felmlee, et al.
Journal of Virology|August 17, 2012
Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cellsDaniel Da Costa, Marine Turek, Daniel J Felmlee, et al.
Viruses|December 4, 2012
Neutralizing antibodies and pathogenesis of hepatitis C virus infectionSamira Fafi-Kremer, Catherine Fauvelle, Daniel J Felmlee, et al.
Gut|October 14, 2010
Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infectionSimon H Bridge, David A Sheridan, Daniel J Felmlee, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Clinical Liver Disease|April 18, 2019
Lipid interactions influence hepatitis C virus susceptibility and resistance to infectionIsaac Thom Shawa, David A Sheridan, Daniel J Felmlee, et al.
Plos One|April 23, 2014
Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein EMathieu Lefèvre, Daniel J Felmlee, Marie Parnot, et al.
Viruses|May 24, 2013
Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver diseaseDaniel J Felmlee, Mohamed Lamine Hafirassou, Mathieu Lefevre, et al.
The Lancet. Infectious Diseases|June 16, 2016
New perspectives for preventing hepatitis C virus liver graft infectionDaniel J Felmlee, Audrey Coilly, Raymond T Chung, et al.
Current Opinion in Virology|January 15, 2014
Entry of hepatitis B and C viruses - recent progress and future impactThomas F Baumert, Luke Meredith, Yi Ni, et al.
Journal of Hepatology|July 2, 2011
HCV and the hepatic lipid pathway as a potential treatment targetMargaret F Bassendine, David A Sheridan, Daniel J Felmlee, et al.
Microbial Pathogenesis|March 19, 2013
Hepatitis C virus vaccines--progress and perspectivesCatherine Fauvelle, Quentin Lepiller, Daniel J Felmlee, et al.
Journal of Virology|August 17, 2012
Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cellsDaniel Da Costa, Marine Turek, Daniel J Felmlee, et al.
Viruses|December 4, 2012
Neutralizing antibodies and pathogenesis of hepatitis C virus infectionSamira Fafi-Kremer, Catherine Fauvelle, Daniel J Felmlee, et al.
Gut|October 14, 2010
Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infectionSimon H Bridge, David A Sheridan, Daniel J Felmlee, et al.
Pageof 3